Skip to main content

How we treat

This Journal of Hematology & Oncology series will focus on guidelines, consensus, and multidisciplinary approaches on cancers and blood disorders. All submissions to this series need to be pre-approved.

Prospective authors should contact the Editorial Office for pre-approval with the outline of their paper, the lead author name, and institution.

Manuscripts sponsored by pharmaceutical companies will not be considered.

© xixinxing / Fotolia.

  1. Sickle cell disease (SCD), which affects approximately 100,000 individuals in the USA and more than 3 million worldwide, is caused by mutations in the βb globin gene that result in sickle hemoglobin production...

    Authors: A. M. Brandow and R. I. Liem
    Citation: Journal of Hematology & Oncology 2022 15:20
  2. The consensus recommendations in 2018 from The Chinese Society of Hematology (CSH) on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation (allo-HSCT) f...

    Authors: Xiao-hui Zhang, Jing Chen, Ming-Zhe Han, He Huang, Er-lie Jiang, Ming Jiang, Yong-rong Lai, Dai-hong Liu, Qi-Fa Liu, Ting Liu, Han-yun Ren, Yong-Ping Song, Zi-min Sun, Xiao-wen Tang, Jian-min Wang, De-pei Wu…
    Citation: Journal of Hematology & Oncology 2021 14:145
  3. Mature B cell neoplasms, previously indolent non-Hodgkin lymphomas (iNHLs), are a heterogeneous group of malignancies sharing similar disease courses and treatment paradigms. Most patients with iNHL have an ex...

    Authors: Melissa Lumish, Lorenzo Falchi, Brandon S. Imber, Michael Scordo, Gottfried von Keudell and Erel Joffe
    Citation: Journal of Hematology & Oncology 2021 14:5